Penetratin — NCs (Penetratin/siRNA core)
Sequence: RQIKIWFQNRRMKWKK
| Experiment Id | EXP001883 |
|---|---|
| Paper | Fine Tuning of Core–Shell Structure of Hyaluronic Acid/Cell-Penetrating Peptides/siRNA Nanoparticles |
| Peptide | Penetratin — NCs (Penetratin/siRNA core) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | CPP/siRNA N/P = 4:1 (complete complexation); HA coated by adsorption to produce NPs-1/NPs-2/NPs-3. |
| Formulation Format | Core–shell nanoparticle (Penetratin/siRNA core; hyaluronic acid shell for NPs) |
| Formulation Components | Core: penetratin-condensed LOX-1 siRNA (NCs). Shell: Penetratin/siRNA core; HAase-responsive de-shielding in plaques/macrophage environment. |
| Size Nm | 124.90 |
| Zeta Mv | 21.40 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Male apoE-deficient mice on high-cholesterol diet (16 weeks induction) followed by 12-week treatment. |
| Administration Route | Tail vein (i.v.) injection; 1.5 mg/kg siRNA, twice per week for 12 weeks (pharmacodynamic efficacy). |
| Output Type | In vivo functional delivery: anti-atherosclerotic efficacy (lesion area, lipid, inflammation markers) |
| Output Value | LOX-1 siRNA formulations reduced aortic root lesion area and lipid accumulation; NPs-3 showed the strongest reduction and decreased CD68+ macrophage content and MCP-1 vs controls. |
| Output Units | |
| Output Notes | Naked CPP/siRNA nanocomplexes (no HA). In vivo ex vivo imaging (Cy5-siRNA 1 mg/kg) showed higher aorta plaque accumulation for HA-coated NPs (highest for NPs-3) vs free siRNA/NCs; therapeutic study shows best efficacy for NPs-3. |
| Toxicity Notes | |
| Curation Notes |